MINNEAPOLIS, March 11, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced ...
DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199 DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have ...
Find the latest DiaMedica Therapeutics Inc. DMAC analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback